Application of next-generation sequencing in clinical oncology to advance personalized treatment of cancer
With the development and improvement of new sequencing technology, next-generation sequencing （NGS） has been applied increasingly ~n cancer genomics research over the past decade. More recently, NGS has been adopted in clinical oncology to advance personalized treatment of cancer. NGS is used to ide...
Saved in:
| Published in | Ai zheng Vol. 31; no. 10; pp. 463 - 470 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Shenzhen Clinical Molecular Diagnostic Engineering Laboratory, BGI-Shenzhen, Shenzhen, Guangdong 518083, P. R. China
01.10.2012
Sun Yat-sen University Cancer Center |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | With the development and improvement of new sequencing technology, next-generation sequencing （NGS） has been applied increasingly ~n cancer genomics research over the past decade. More recently, NGS has been adopted in clinical oncology to advance personalized treatment of cancer. NGS is used to identify novel and rare cancer mutations, detect familial cancer mutation carriers, and provide molecular rationale for appropriate targeted therapy. Compared to traditional sequencing, NGS holds many advantages, such as the ability to fully sequence all types of mutations for a large number of genes （hundreds to thousands） in a single test at a relatively low cost. However, significant challenges, particularly with respect to the requirement for simpler assays, more flexible throughput, shorter turnaround time, and most importantly, easier data analysis and interpretation, will have to be overcome to translate NGS to the bedside of cancer patients. Overall, continuous dedication to apply NGS in clinical oncology practice will enable us to be one step closer to personalized medicine. |
|---|---|
| AbstractList | With the development and improvement of new sequencing technology, next-generation sequencing (NGS) has been applied increasingly in cancer genomics research over the past decade. More recently, NGS has been adopted in clinical oncology to advance personalized treatment of cancer. NGS is used to identify novel and rare cancer mutations, detect familial cancer mutation carriers, and provide molecular rationale for appropriate targeted therapy. Compared to traditional sequencing, NGS holds many advantages, such as the ability to fully sequence all types of mutations for a large number of genes (hundreds to thousands) in a single test at a relatively low cost. However, significant challenges, particularly with respect to the requirement for simpler assays, more flexible throughput, shorter turnaround time, and most importantly, easier data analysis and interpretation, will have to be overcome to translate NGS to the bedside of cancer patients. Overall, continuous dedication to apply NGS in clinical oncology practice will enable us to be one step closer to personalized medicine.With the development and improvement of new sequencing technology, next-generation sequencing (NGS) has been applied increasingly in cancer genomics research over the past decade. More recently, NGS has been adopted in clinical oncology to advance personalized treatment of cancer. NGS is used to identify novel and rare cancer mutations, detect familial cancer mutation carriers, and provide molecular rationale for appropriate targeted therapy. Compared to traditional sequencing, NGS holds many advantages, such as the ability to fully sequence all types of mutations for a large number of genes (hundreds to thousands) in a single test at a relatively low cost. However, significant challenges, particularly with respect to the requirement for simpler assays, more flexible throughput, shorter turnaround time, and most importantly, easier data analysis and interpretation, will have to be overcome to translate NGS to the bedside of cancer patients. Overall, continuous dedication to apply NGS in clinical oncology practice will enable us to be one step closer to personalized medicine. R73; With the development and improvement of new sequencing technology,next-generation sequencing (NGS) has been applied increasingly in cancer genomics research over the past decade.More recently,NGS has been adopted in clinical oncology to advance personalized treatment of cancer.NGS is used to identify novel and rare cancer mutations,detect familial cancer mutation carriers,and provide molecular rationale for appropriate targeted therapy.Compared to traditional sequencing,NGS holds many advantages,such as the ability to fully sequence all types of mutations for a large number of genes (hundreds to thousands) in a single test at a relatively low cost.However,significant challenges,particularly with respect to the requirement for simpler assays,more flexible throughput,shorter turnaround time,and most importantly,easier data analysis and interpretation,will have to be overcome to translate NGS to the bedside of cancer patients.Overall,continuous dedication to apply NGS in clinical oncology practice will enable us to be one step closer to personalized medicine. With the development and improvement of new sequencing technology, next-generation sequencing (NGS) has been applied increasingly in cancer genomics research over the past decade. More recently, NGS has been adopted in clinical oncology to advance personalized treatment of cancer. NGS is used to identify novel and rare cancer mutations, detect familial cancer mutation carriers, and provide molecular rationale for appropriate targeted therapy. Compared to traditional sequencing, NGS holds many advantages, such as the ability to fully sequence all types of mutations for a large number of genes (hundreds to thousands) in a single test at a relatively low cost. However, significant challenges, particularly with respect to the requirement for simpler assays, more flexible throughput, shorter turnaround time, and most importantly, easier data analysis and interpretation, will have to be overcome to translate NGS to the bedside of cancer patients. Overall, continuous dedication to apply NGS in clinical oncology practice will enable us to be one step closer to personalized medicine. With the development and improvement of new sequencing technology, next-generation sequencing （NGS） has been applied increasingly ~n cancer genomics research over the past decade. More recently, NGS has been adopted in clinical oncology to advance personalized treatment of cancer. NGS is used to identify novel and rare cancer mutations, detect familial cancer mutation carriers, and provide molecular rationale for appropriate targeted therapy. Compared to traditional sequencing, NGS holds many advantages, such as the ability to fully sequence all types of mutations for a large number of genes （hundreds to thousands） in a single test at a relatively low cost. However, significant challenges, particularly with respect to the requirement for simpler assays, more flexible throughput, shorter turnaround time, and most importantly, easier data analysis and interpretation, will have to be overcome to translate NGS to the bedside of cancer patients. Overall, continuous dedication to apply NGS in clinical oncology practice will enable us to be one step closer to personalized medicine. |
| Author | Yan-Fang Guan Gai-Rui Li Rong-Jiao Wang Yu-Ting Yi Ling Yang Dan Jiang Xiao-Ping Zhang Yin Peng |
| AuthorAffiliation | Shenzhen Clinical Molecular Diagnostic Engineering Laboratory, BGI-Shenzhen, Shenzhen, Guangdong 518083, P. R. China. |
| AuthorAffiliation_xml | – name: Shenzhen Clinical Molecular Diagnostic Engineering Laboratory, BGI-Shenzhen, Shenzhen, Guangdong 518083, P. R. China – name: Author's Affiliation: Shenzhen Clinical Molecular Diagnostic Engineering Laboratory, BGI-Shenzhen, Shenzhen, Guangdong 518083, P. R. China |
| Author_xml | – sequence: 1 givenname: Yan-Fang surname: Guan fullname: Guan, Yan-Fang – sequence: 2 givenname: Gai-Rui surname: Li fullname: Li, Gai-Rui – sequence: 3 givenname: Rong-Jiao surname: Wang fullname: Wang, Rong-Jiao – sequence: 4 givenname: Yu-Ting surname: Yi fullname: Yi, Yu-Ting – sequence: 5 givenname: Ling surname: Yang fullname: Yang, Ling – sequence: 6 givenname: Dan surname: Jiang fullname: Jiang, Dan – sequence: 7 givenname: Xiao-Ping surname: Zhang fullname: Zhang, Xiao-Ping – sequence: 8 givenname: Yin surname: Peng fullname: Peng, Yin |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22980418$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kUlvFDEQhS0URBY4ckVGXLj04K3b7QtSFLFEisQFpNwsj7vc8chjd-yehOTX48lMooDEyUt99fxc7xgdxBQBobeULFrJ2Se7sgtC2YISRrsX6IgqIRohusuDuieENKKTl4fouJQVIYIq2b9Ch4ypvh76I7Q6nabgrZl9ijg5HOH33IwQIe-uClxvIFofR-wjtsHHCgecok0hjXd4TtgMNyZawBPkkqIJ_h4GPGcw8xrivBW123p-jV46Ewq82a8n6NfXLz_PvjcXP76dn51eNFYIOjdgHOEM3NIJ4bhkjHLWqZbx3lmnnJSml9yQThFjhWzJkjpoO-LkoOxyUISfoM873WmzXMNgq4lsgp6yX5t8p5Px-u9K9Fd6TDeaSylFy6vAh53ArYnOxFGv0ibXjxUN96zOejtWVqmP-2dyqjMqs177YiEEEyFtiqakp9Up6dqKvnvu6MnKYwwV4DvA5lRKBqetnx8CqAZ9qFp6G7auYetqQD-EXbuaf7oehf_Hv9_zVymO1zXTpwbBheolI_wPt9e4xg |
| CitedBy_id | crossref_primary_10_3390_cimb46110744 crossref_primary_10_5946_ce_2019_127 crossref_primary_10_1007_s11864_022_00942_8 crossref_primary_10_18632_oncotarget_25643 crossref_primary_10_1080_07853890_2024_2353893 crossref_primary_10_1245_s10434_021_10945_8 crossref_primary_10_1016_j_gastre_2022_10_001 crossref_primary_10_1016_j_canlet_2012_11_050 crossref_primary_10_1016_j_lungcan_2020_05_026 crossref_primary_10_1080_10428194_2017_1399312 crossref_primary_10_1371_journal_pone_0143199 crossref_primary_10_7717_peerj_9684 crossref_primary_10_1080_14737159_2024_2408740 crossref_primary_10_1186_s12864_022_08752_w crossref_primary_10_5858_arpa_2016_0117_RA crossref_primary_10_5009_gnl19011 crossref_primary_10_3390_ht9010001 crossref_primary_10_3389_pore_2023_1611391 crossref_primary_10_1111_codi_13334 crossref_primary_10_1016_j_clbc_2016_02_016 crossref_primary_10_1016_j_rineng_2023_101421 crossref_primary_10_3390_jpm11080730 crossref_primary_10_1002_gcc_22352 crossref_primary_10_3390_cancers7030859 crossref_primary_10_3390_genes13091583 crossref_primary_10_36106_ijsr_6402057 crossref_primary_10_1016_j_canlet_2012_12_028 crossref_primary_10_1016_j_critrevonc_2020_103113 crossref_primary_10_1186_s12967_017_1353_y crossref_primary_10_2174_0113892029285310231227105503 crossref_primary_10_1002_cncy_21597 crossref_primary_10_1016_j_imu_2021_100762 crossref_primary_10_3390_bios12030170 crossref_primary_10_1016_j_bbrep_2023_101519 crossref_primary_10_1055_s_0043_1774752 crossref_primary_10_1177_23247096221141190 crossref_primary_10_1016_j_canlet_2012_11_025 crossref_primary_10_1016_j_semradonc_2023_03_001 crossref_primary_10_1186_s12929_023_00926_2 crossref_primary_10_1002_cai2_115 crossref_primary_10_1016_j_canlet_2012_11_029 crossref_primary_10_3390_cancers13153827 crossref_primary_10_3389_fimmu_2021_780134 crossref_primary_10_1186_s12967_022_03230_z crossref_primary_10_1016_j_jpi_2024_100408 crossref_primary_10_3389_fmed_2022_950309 crossref_primary_10_1002_bab_2356 crossref_primary_10_18632_oncotarget_26675 crossref_primary_10_1007_s11121_016_0729_1 crossref_primary_10_1186_s12911_020_1060_0 crossref_primary_10_3389_fphar_2024_1400186 crossref_primary_10_3389_fonc_2022_910494 crossref_primary_10_3390_bioengineering10060673 crossref_primary_10_1002_mgg3_2141 crossref_primary_10_1002_pros_24373 crossref_primary_10_18632_oncotarget_11061 crossref_primary_10_1186_s12935_020_01438_x crossref_primary_10_1016_j_canlet_2012_10_018 crossref_primary_10_3389_fimmu_2024_1476494 crossref_primary_10_3390_ijms21031054 crossref_primary_10_1016_j_gastrohep_2021_12_011 crossref_primary_10_25259_SRJHS_16_2024 crossref_primary_10_3390_mi12101147 crossref_primary_10_1089_omi_2024_0175 crossref_primary_10_3390_diseases11020072 crossref_primary_10_1002_jmv_28693 crossref_primary_10_3390_life12070956 crossref_primary_10_3788_CJL240447 |
| ClassificationCodes | R73 |
| ContentType | Journal Article |
| Copyright | Copyright © Wanfang Data Co. Ltd. All Rights Reserved. Chinese Journal of Cancer 2012 |
| Copyright_xml | – notice: Copyright © Wanfang Data Co. Ltd. All Rights Reserved. – notice: Chinese Journal of Cancer 2012 |
| DBID | 2RA 92L CQIGP W91 ~WA AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 2B. 4A8 92I 93N PSX TCJ 5PM |
| DOI | 10.5732/cjc.012.10216 |
| DatabaseName | 中文科技期刊数据库 中文科技期刊数据库-CALIS站点 中文科技期刊数据库-7.0平台 中文科技期刊数据库-医药卫生 中文科技期刊数据库- 镜像站点 CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Wanfang Data Journals - Hong Kong WANFANG Data Centre Wanfang Data Journals 万方数据期刊 - 香港版 China Online Journals (COJ) China Online Journals (COJ) PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | Application of next-generation sequencing in clinical oncology to advance personalized treatment of cancer |
| EISSN | 1944-446X |
| EndPage | 470 |
| ExternalDocumentID | PMC3777453 ez201210002 22980418 10_5732_cjc_012_10216 43498720 |
| Genre | Journal Article Review |
| GroupedDBID | --- -05 -0E -S~ 2B. 2C~ 2RA 3V. 5VS 5XA 5XF 92F 92I 92L 92M 93N 93R ACGFS ADBBV ADINQ ADRAZ AENEX AFGXO AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP BCNDV BENPR BPHCQ BVXVI C24 CCEZO CHBEP CIEJG CQIGP CW9 DIK EJD F5P FA0 GROUPED_DOAJ HYE IAO IHR IHW ITC JUIAU KQ8 M48 M~E OK1 P2P PIMPY PQQKQ PROAC R-E RBZ RNS ROL RPM RSV RT5 S.. T8U TCJ TGQ U1F U1G U5E U5O W91 ~WA AAYXX ABJNI CITATION PGMZT CGR CUY CVF ECM EIF H13 NPM 7X8 4A8 PSX 5PM |
| ID | FETCH-LOGICAL-c441t-eaf032efbf44f3722132695238fcf9f77a873a0690ac4750b1fe560f7d9cbd903 |
| IEDL.DBID | M48 |
| ISSN | 1000-467X |
| IngestDate | Thu Aug 21 18:13:27 EDT 2025 Thu May 29 04:02:53 EDT 2025 Fri Jul 11 09:07:50 EDT 2025 Thu Apr 03 06:59:48 EDT 2025 Thu Apr 24 23:04:39 EDT 2025 Tue Jul 01 02:34:55 EDT 2025 Wed Feb 14 10:45:25 EST 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | false |
| Issue | 10 |
| Keywords | cancer Next-generation sequencing (NGS) personalized treatment |
| Language | English |
| License | This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License, which allows readers to alter, transform, or build upon the article and then distribute the resulting work under the same or similar license to this one. The work must be attributed back to the original author and commercial use is not permitted without specific permission. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c441t-eaf032efbf44f3722132695238fcf9f77a873a0690ac4750b1fe560f7d9cbd903 |
| Notes | Next-generation sequencing （NGS）, cancer, personalized treatment 44-1195/R With the development and improvement of new sequencing technology, next-generation sequencing （NGS） has been applied increasingly ~n cancer genomics research over the past decade. More recently, NGS has been adopted in clinical oncology to advance personalized treatment of cancer. NGS is used to identify novel and rare cancer mutations, detect familial cancer mutation carriers, and provide molecular rationale for appropriate targeted therapy. Compared to traditional sequencing, NGS holds many advantages, such as the ability to fully sequence all types of mutations for a large number of genes （hundreds to thousands） in a single test at a relatively low cost. However, significant challenges, particularly with respect to the requirement for simpler assays, more flexible throughput, shorter turnaround time, and most importantly, easier data analysis and interpretation, will have to be overcome to translate NGS to the bedside of cancer patients. Overall, continuous dedication to apply NGS in clinical oncology practice will enable us to be one step closer to personalized medicine. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.5732/cjc.012.10216 |
| PMID | 22980418 |
| PQID | 1081873065 |
| PQPubID | 23479 |
| PageCount | 8 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3777453 wanfang_journals_ez201210002 proquest_miscellaneous_1081873065 pubmed_primary_22980418 crossref_citationtrail_10_5732_cjc_012_10216 crossref_primary_10_5732_cjc_012_10216 chongqing_primary_43498720 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2012-10-01 |
| PublicationDateYYYYMMDD | 2012-10-01 |
| PublicationDate_xml | – month: 10 year: 2012 text: 2012-10-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Ai zheng |
| PublicationTitleAlternate | Chinese Journal of Cancer |
| PublicationTitle_FL | Chinese Journal of Cancer |
| PublicationYear | 2012 |
| Publisher | Shenzhen Clinical Molecular Diagnostic Engineering Laboratory, BGI-Shenzhen, Shenzhen, Guangdong 518083, P. R. China Sun Yat-sen University Cancer Center |
| Publisher_xml | – name: Shenzhen Clinical Molecular Diagnostic Engineering Laboratory, BGI-Shenzhen, Shenzhen, Guangdong 518083, P. R. China – name: Sun Yat-sen University Cancer Center |
| References | 15024741 - Hum Mutat. 2004 Apr;23(4):397-8 21990299 - JAMA. 2011 Oct 12;306(14):1557-65 22874498 - J Mol Diagn. 2012 Sep;14(5):467-75 22271477 - J Clin Oncol. 2012 Feb 20;30(6):647-60 21305653 - Hum Mutat. 2011 Mar;32(3):335-44 20016485 - Nature. 2010 Jan 14;463(7278):191-6 22649089 - Sci Transl Med. 2012 May 30;4(136):136ra68 21642962 - Nature. 2011 Jul 7;475(7354):101-5 22751458 - Nat Rev Gastroenterol Hepatol. 2012 Aug;9(8):477-86 22369376 - Expert Rev Mol Diagn. 2012 Mar;12(2):159-73 22313048 - Genet Test Mol Biomarkers. 2012 Jun;16(6):580-91 15637391 - J Clin Oncol. 2005 Jan 10;23(2):276-92 18337604 - N Engl J Med. 2008 Mar 13;358(11):1148-59 20616022 - Proc Natl Acad Sci U S A. 2010 Jul 13;107(28):12629-33 271968 - Proc Natl Acad Sci U S A. 1977 Dec;74(12):5463-7 22389664 - PLoS One. 2012;7(2):e27835 21109225 - Am J Hum Genet. 2010 Dec 10;87(6):873-81 22216297 - PLoS One. 2011;6(12):e29500 18987736 - Nature. 2008 Nov 6;456(7218):66-72 19657110 - N Engl J Med. 2009 Sep 10;361(11):1058-66 16875939 - Cancer Genet Cytogenet. 2006 Aug;169(1):62-8 22848739 - PLoS One. 2012;7(7):e42164 21822268 - Nat Genet. 2011 Sep;43(9):875-8 22648865 - Top Curr Chem. 2014;336:1-18 22495713 - Tumori. 2012 Jan-Feb;98(1):126-36 21228398 - Sci Transl Med. 2011 Jan 12;3(65):65ra4 20351699 - Nat Rev Clin Oncol. 2010 May;7(5):251-65 21781349 - J Transl Med. 2011;9:119 22138691 - Nat Genet. 2012 Jan;44(1):17-9 22722193 - Nature. 2012 Jun 21;486(7403):353-60 22375550 - Clin Genet. 2012 Jun;81(6):503-10 22160009 - Hematology Am Soc Hematol Educ Program. 2011;2011:30-5 22500971 - Expert Opin Biol Ther. 2012 Jun;12 Suppl 1:S19-26 21505136 - JAMA. 2011 Apr 20;305(15):1577-84 20473311 - Nat Genet. 2010 Jun;42(6):486-8 22369100 - BMC Genomics. 2011 Dec 23;12 Suppl 5:S5 16551709 - JAMA. 2006 Mar 22;295(12):1379-88 22147957 - Clin Biochem Rev. 2011 Nov;32(4):177-95 22133722 - Sci Transl Med. 2011 Nov 30;3(111):111ra121 21657839 - Biomark Med. 2011 Jun;5(3):293-305 21049026 - PLoS One. 2010;5(10):e13630 22426013 - J Mol Diagn. 2012 May-Jun;14(3):286-93 21695249 - PLoS One. 2011;6(6):e18158 22792313 - PLoS One. 2012;7(7):e40425 21307934 - Nature. 2011 Feb 10;470(7333):214-20 22286582 - Onkologie. 2012;35 Suppl 1:8-12 21917674 - Am J Clin Pathol. 2011 Oct;136(4):527-39 22617168 - Cancer Prev Res (Phila). 2012 Jul;5(7):887-900 |
| References_xml | – reference: 20473311 - Nat Genet. 2010 Jun;42(6):486-8 – reference: 22369100 - BMC Genomics. 2011 Dec 23;12 Suppl 5:S5 – reference: 18987736 - Nature. 2008 Nov 6;456(7218):66-72 – reference: 22751458 - Nat Rev Gastroenterol Hepatol. 2012 Aug;9(8):477-86 – reference: 16551709 - JAMA. 2006 Mar 22;295(12):1379-88 – reference: 20616022 - Proc Natl Acad Sci U S A. 2010 Jul 13;107(28):12629-33 – reference: 20016485 - Nature. 2010 Jan 14;463(7278):191-6 – reference: 22147957 - Clin Biochem Rev. 2011 Nov;32(4):177-95 – reference: 22369376 - Expert Rev Mol Diagn. 2012 Mar;12(2):159-73 – reference: 22648865 - Top Curr Chem. 2014;336:1-18 – reference: 21305653 - Hum Mutat. 2011 Mar;32(3):335-44 – reference: 22160009 - Hematology Am Soc Hematol Educ Program. 2011;2011:30-5 – reference: 22133722 - Sci Transl Med. 2011 Nov 30;3(111):111ra121 – reference: 15637391 - J Clin Oncol. 2005 Jan 10;23(2):276-92 – reference: 22313048 - Genet Test Mol Biomarkers. 2012 Jun;16(6):580-91 – reference: 21307934 - Nature. 2011 Feb 10;470(7333):214-20 – reference: 22495713 - Tumori. 2012 Jan-Feb;98(1):126-36 – reference: 22138691 - Nat Genet. 2012 Jan;44(1):17-9 – reference: 21990299 - JAMA. 2011 Oct 12;306(14):1557-65 – reference: 18337604 - N Engl J Med. 2008 Mar 13;358(11):1148-59 – reference: 21657839 - Biomark Med. 2011 Jun;5(3):293-305 – reference: 271968 - Proc Natl Acad Sci U S A. 1977 Dec;74(12):5463-7 – reference: 20351699 - Nat Rev Clin Oncol. 2010 May;7(5):251-65 – reference: 21642962 - Nature. 2011 Jul 7;475(7354):101-5 – reference: 22286582 - Onkologie. 2012;35 Suppl 1:8-12 – reference: 22271477 - J Clin Oncol. 2012 Feb 20;30(6):647-60 – reference: 22500971 - Expert Opin Biol Ther. 2012 Jun;12 Suppl 1:S19-26 – reference: 22649089 - Sci Transl Med. 2012 May 30;4(136):136ra68 – reference: 22375550 - Clin Genet. 2012 Jun;81(6):503-10 – reference: 21781349 - J Transl Med. 2011;9:119 – reference: 15024741 - Hum Mutat. 2004 Apr;23(4):397-8 – reference: 22216297 - PLoS One. 2011;6(12):e29500 – reference: 21822268 - Nat Genet. 2011 Sep;43(9):875-8 – reference: 19657110 - N Engl J Med. 2009 Sep 10;361(11):1058-66 – reference: 22792313 - PLoS One. 2012;7(7):e40425 – reference: 21695249 - PLoS One. 2011;6(6):e18158 – reference: 22874498 - J Mol Diagn. 2012 Sep;14(5):467-75 – reference: 21228398 - Sci Transl Med. 2011 Jan 12;3(65):65ra4 – reference: 21109225 - Am J Hum Genet. 2010 Dec 10;87(6):873-81 – reference: 22426013 - J Mol Diagn. 2012 May-Jun;14(3):286-93 – reference: 21505136 - JAMA. 2011 Apr 20;305(15):1577-84 – reference: 16875939 - Cancer Genet Cytogenet. 2006 Aug;169(1):62-8 – reference: 22848739 - PLoS One. 2012;7(7):e42164 – reference: 21049026 - PLoS One. 2010;5(10):e13630 – reference: 22389664 - PLoS One. 2012;7(2):e27835 – reference: 21917674 - Am J Clin Pathol. 2011 Oct;136(4):527-39 – reference: 22617168 - Cancer Prev Res (Phila). 2012 Jul;5(7):887-900 – reference: 22722193 - Nature. 2012 Jun 21;486(7403):353-60 |
| SSID | ssj0041978 |
| Score | 1.8408662 |
| SecondaryResourceType | review_article |
| Snippet | With the development and improvement of new sequencing technology, next-generation sequencing （NGS） has been applied increasingly ~n cancer genomics research... With the development and improvement of new sequencing technology, next-generation sequencing (NGS) has been applied increasingly in cancer genomics research... R73; With the development and improvement of new sequencing technology,next-generation sequencing (NGS) has been applied increasingly in cancer genomics... |
| SourceID | pubmedcentral wanfang proquest pubmed crossref chongqing |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 463 |
| SubjectTerms | High-Throughput Nucleotide Sequencing - economics High-Throughput Nucleotide Sequencing - methods Humans Mutation Neoplasms - genetics Precision Medicine Review Sequence Analysis, DNA 个性化 临床实践 基因突变 基因组学 应用 测序技术 癌症治疗 肿瘤学 |
| Title | Application of next-generation sequencing in clinical oncology to advance personalized treatment of cancer |
| URI | http://lib.cqvip.com/qk/90720X/201210/43498720.html https://www.ncbi.nlm.nih.gov/pubmed/22980418 https://www.proquest.com/docview/1081873065 https://d.wanfangdata.com.cn/periodical/ez201210002 https://pubmed.ncbi.nlm.nih.gov/PMC3777453 |
| Volume | 31 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwEB5BEYgL4llSSmUkxIks8SPr5IQqRFUhLSdW2pvlOPa2VeW0262g_fXM5FVWCxLXeGI5nrHnm8z4M8D7Oq-IJF2lhN1TlWPMWoSap5UPVitrvW2Pi82-T4_n6tsiX9xRCvUTePXX0I7uk5qvzie_Lm8-44JH_DrJtRSf3Jmb4D5LLAR8eh8eoFPStEZnakwoKF7q7lRclqW4Nyw6us3t14li4aSJy0t0HJuuagt_bpdRPvxpY7Bx-YeHOnoKT3poyQ47W3gG93x8Do9mffL8BZwd3iWrWRNYpKB32dJOt4_6qmocEjuNbDgyyZrYElvfsHXD-ooBdjFA-Ftfs7FWnTp11L56CfOjrz--HKf9VQupQzy0Tr0NmRQ-VEGpILUQGKROSwxSi-BCGbS2hZaWWI2tUwgyKh48YqWg69JVdZnJV7ATm-hfA-N58LgLFEWOyFJwVXnOnfSIk4IvrfcJ7I0zbC46Sg2jpCoLLbIEPg5TblxPUk53ZZwbDFZIWwa1ZVBbptVWAh9G8aGrfwi-G_RncP1QUsRG31xfEUEqx29DJJbAbqfPsSshSqJnKhLQG5oeBYibe7Mlnp60HN1S49fnMoH93ibMYNrG3woi0iNftPcfw3oDj0m-KyDch5316tq_RSC0rg5aEz9o_1D9BqOCCMQ |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Application+of+next-generation+sequencing+in+clinical+oncology+to+advance+personalized+treatment+of+cancer&rft.jtitle=Ai+zheng&rft.au=Guan%2C+Yan-Fang&rft.au=Li%2C+Gai-Rui&rft.au=Wang%2C+Rong-Jiao&rft.au=Yi%2C+Yu-Ting&rft.date=2012-10-01&rft.issn=1000-467X&rft.volume=31&rft.issue=10&rft.spage=463&rft_id=info:doi/10.5732%2Fcjc.012.10216&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_s | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F90720X%2F90720X.jpg http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.wanfangdata.com.cn%2Fimages%2FPeriodicalImages%2Fez%2Fez.jpg |